PlainRecalls
FDA Drug Moderate Class II Terminated

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

Reported: August 24, 2022 Initiated: July 28, 2022 #D-1343-2022

Product Description

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

Reason for Recall

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Details

Units Affected
7,872/30 count bottles
Distribution
Product was distributed nationwide.
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 7,872/30 count bottles.
Why was this product recalled?
CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 24, 2022. Severity: Moderate. Recall number: D-1343-2022.